Kornimate/medical-research-clean huggingface dataset:
middle cerebral to umbilical artery doppler ratio and amniotic fluid volume measurement in post-date pregnancies in king khalid military central city

Conditions: Pregnancy, Prolonged

Summary: the aim of this study is to assess the values of mca pi / ua pi and mca ri / ua ri ratios and amniotic fluid volume in predicting the adverse perinatal fetal outcome in uncomplicated postdate pregnancy

the study will be a case-control study that will be conducted at banha university hospital and afhsr in saudi arabia after the approval of institutional ethical committee. one hundred pregnant women will be recruited from antenatal clinic. starting from november 2022. an informed consent will be obtained from the patients . the patients will be subdivided into two groups: group 1(control group):consist of 100 pregnant females with gestational age 37-40 weeks. group 2 (post date group):consist of 100 pregnant females with gestational age 41 weeks or more. inclusion criteria: 1. singleton, viable fetus in the vertex presentation. 2. history of regular menstrual cycles. 3. gestational age calculated from the first day of last menstryal period or by first-trimester or second-trimester (before 20 weeks) ultrasound examination. 4. no obstetric or medical complications of pregnancy apart from post-date pregnancy all patients will be subjected to: 1. detailed history: including, personal history, menstural history, obstetric history, present history and past history. 2. physical examination: general, abdominal and pelvic examination. 3. investigations: including, a- ultrasound examintion for amniotic fluid index (afi) measurement. b- doppler studies: i - middle cerebral artery pulsatility index (mca -pi) and resistace index(mca-ri). ii - umbilical artery pulsatility index (ua-pi) and resistance index (ua-ri). iii - cerebro-placental ratio (cpr).

Eligibility criteria:
inclusion criteria: 1. singleton, viable fetus in the vertex presentation 2. history of regular menstrual cycles 3. gestational age calculated from the first day of last menstryal period or by first-trimester or second-trimester (before 20 weeks) ultrasound examination 4. no obstetric or medical complications of pregnancy apart from post-date pregnancy exclusion criteria: 1. patients unsure of their dates 2. medical disorders with pregnancy as (hypertension, diabetes mellitus or rh isoimmunization) 3. prelabor rupture of membranes 4. polyhydramnios 5. women with multiple pregnancy 6. congenital fetal anomalies 7. antepartum hemorrhage 8. previus cesarean section 9. fetal malpresentation
effect of opioid cessation on opioid-induced esophageal dysfunction

Conditions: Opioid-Induced Esophageal Dysfunction

Summary: the purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (oied).


Eligibility criteria:
inclusion criteria: - patients enrolled in the pain rehabilitation center for opioid cessation, with or without esophageal symptoms. exclusion criteria: * inability to provide informed consent. * patients with previous gastroesophageal surgery or pneumatic dilation. * esophageal botulinum toxin injection within the prior 12 months. * esophageal stricture * achalasia types i and ii * allergy to lidocaine or other local anesthetics * subjects on anticoagulation * bilateral nasal obstruction * pregnancy or breast feeding
vacuum device for hemostasis in obstetrics and gynecology

Conditions: Primary Postpartum Hemorrhage; Administration of Sulprostone; Vaginal Childbirth

Summary: postpartum hemorrhage (pph), is the leading cause of maternal mortality and is responsible for approximately 25% of maternal mortality deaths.it is defined as blood loss in excess of 500 ml following vaginal childbirth. primary (immediate) pph occurs within the first 24 hours after delivery. in clinical practice, if after giving birth, the placenta is not expelled naturally, an active management should be triggered. after obstetric maneuvers therapeutic, options begin with uterotonic treatments before considering invasive treatments such as embolization, vessel ligation and hysterectomy. however, the morbidity associated with these techniques and the desire to preserve fertility mean that new therapeutic solutions have been conceived, which has recently led to the development of an innovative intrauterine hemostasis medical device : a hemostatic intrauterine suction cup. assuming that postpartum hemorrhages are mainly due to uterine atony, we propose in this biomedical research, the study of a new medical device. our hypothesis is that the uterine walls will append to the walls of the suction cup after the latter is put under vacuum. the actuation of the suction cup will lead to the aspiration of all sides of the uterus. considering that postpartum haemorrhage is an emergency situation where vital prognosis of the patient is engaged, we selected to collect the consent of the patient using an emergengy procedure.

in this study, as a first pass in human of this innovative non ce marked medical device, we aim to demonstrate the feasibility of using the hemostatic intrauterine suction cup for patients who present primary pph (blood loss ≥ 500ml) after a vaginal delivery requiring administration of nalador®. we will evaluate the placement of hemostatic suction cup in the uterus, the application of vacuum and its removal from the uterus.

Eligibility criteria:
inclusion criteria: * women between 18 and 45 years old * patient under loco-regional anesthesia * patient who presents primary postpartum hemorrhage (blood loss ≥ 500ml) after a vaginal childbirth requiring administration of nalador®. * affiliation to the french social security system or equivalent * patient who has signed a consent to participate exclusion criteria: * patient with a uterine malformation * patient allergic to silicon * patient under general anesthesia * patient who delivered via caesarean section * patient with fever or suspected infection during labor * person deprived of freedom by judicial or administrative decision * person hospitalized without their consent * person under legal protection * person hospitalized for psychiatric care
short-term effects & safety of an accelerated intravenous iron regimen in patients with heart failure

Conditions: Heart Failure; Iron Deficiency Anemia

Summary: intravenous iron replacement has been shown to benefit patients with heart failure and iron deficiency, but the weekly outpatient regimens studied to date are impractical for many patients. our purpose is to evaluate the short-term effects and safety of an accelerated intravenous iron regimen in hospitalized patients with these two conditions.

the purpose of this pilot investigation is to evaluate the short-term hematologic effects and safety of an accelerated intravenous iron regimen in patients with heart failure and iron deficiency. recent investigations have demonstrated improved clinical outcomes with the use of intravenous iron therapy in this patient population, but a weekly regimen administered to ambulatory patients may be inconvenient, impractical, and associated with less than optimal adherence rates for many patients, especially those with reduced functional capacity. the heart failure population is characterized by frequent hospitalizations, which would make an accelerated inpatient regimen a convenient and attractive option for improving heart failure symptoms, exercise tolerance, and quality of life. accelerated regimens have been demonstrated as being both safe and effective in other patient populations, but no studies to date have evaluated this strategy in hospitalized patients with heart failure.

Eligibility criteria:
inclusion criteria: * age \> 18 years * admission to the general cardiology or heart failure services and under the care of a cardiologist at the study institution * new york heart association class ii-iv heart failure * ejection fraction \< 40% * serum hemoglobin \< 12.0 g/dl * ferritin \< 100 ng/ml or 100-300 ng/ml with transferrin saturation (tsat) \< 20% * patients deemed by an attending physician to require intravenous iron therapy based on previous attempts to correct iron deficiency or other patient-specific circumstances exclusion criteria: * anemia of other known etiology (e.g., malignancy, malabsorption syndromes) * use of iron or erythropoietin-stimulating agents within previous 12 weeks * blood transfusion within previous 12 weeks; additionally, if patients receive blood transfusions during the study period, they will remain in the safety analysis but will be excluded from efficacy analysis * active bleeding * known infection at admission * immunosuppressant therapy * renal replacement therapy * known pregnancy * any other criteria deemed by the attending physician to warrant exclusion
instanyl® non-interventional study

Conditions: Breakthrough Cancer Pain

Summary: the aim of this study is to describe the use of instanyl® (intranasal fentanyl spray) in the treatment of breakthrough pain (btp) in cancer patients by success of dose titration and distribution of dose strength. data will be collected at three different time points over a 3 month period.


Eligibility criteria:
* adult cancer patients suffering from btp * instanyl should be prescribed in accordance with the summary of product characteristics (spc) and none of the stated contradictions applies * the decision to prescribe should be made independently of the study * all patients must provide signed informed consent prior to inclusion

Keywords: instanyl non-interventional breakthrough cancer pain btp btcp intranasal fentanyl spray
quantification of nerve stiffness in neuropathies

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; Charcot-Marie-Tooth Disease, Type IA; Anti-MAG Neuropathy

Summary: this project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. patients will be compared with age-matched controls.

the following nerve will be studied bilaterally, in a randomised order: median, ulnar, radial, sciatic and tibial. participants will be asked to remain relaxed during elastography measurements.

Eligibility criteria:
inclusion criteria: * male or female aged 18 to 65 * having social insurance status * having given informed consent * diagnostic of chronic inflammatory demyelinating polyradiculoneuropathy (cidp), cmt1a or anti-mag (peak immunoglobulin m (igm)\>15,000 btu) exclusion criteria: for controls: * person staying in a health or social facility * person unable to understand the protocol and to respect the modalities * person deprived of liberty * person of legal age benefiting from a system of legal protection (guardianship, curators or safeguard of justice) * participation in another biomedical research in progress * diabetes, history of neuromuscular disease for cidp: * person staying in a health or social facility * person unable to understand the protocol and to respect the modalities * person deprived of liberty * person of legal age benefiting from a system of legal protection (guardianship, curators or safeguard of justice) * participation in another biomedical research in progress * mrc score \< 3 for charcot-marie-tooth type 1 (cmt1) and anti-mag: * person staying in a health or social facility * person unable to understand the protocol and to respect the modalities * person deprived of liberty * person of legal age benefiting from a system of legal protection (guardianship, curators or safeguard of justice) * participation in another biomedical research in progress
are there changes in the nerve fiber layer (nfl) after lowering of eye pressure?

Conditions: Glaucoma

Summary: the aim of this study was to evaluate structural and functional improvement after lowering intraocular pressure (iop) in patients with glaucoma using spectral domain optical coherence tomography (sd-oct), visual field (vf) testing, and visual evoked potential (vep).

glaucoma exhibits characteristic changes to the optic nerve in the back of the eye. the optic nerve is formed when fibers that overlay the retina come together. this layer is called the retinal nerve fiber layer (rnfl). optical coherence tomography (oct) is a machine that scans eyes and has the capability of measuring thickness of various layers in the retina and rnfl. this provides important anatomical information. vep (visual evoked potential) is an imaging system that measures electrical signals from the eye to the brain by using electrodes placed on the forehead and back of head. this is similar in principal to an electrocardiogram of the heart. visual field testing is done to evaluate the extent of side vision loss caused by various diseases of the eye, including glaucoma. this testing is performed as you stare at a small light directly in front of your eye while lights flash one at a time in every direction on a screen surrounding the central light. you push a button each time you see a flash out of the corner of your eye. lowering intraocular pressure (iop) in the eye has been shown to result in reversal of glaucoma changes of the optic nerve in some patients. it has also been suggested that improvement in function (visual field) has been associated with improved optic nerve appearance. this study seeks to provide evidence for reversal of disc appearance and visual function following iop lowering interventions.

Eligibility criteria:
inclusion criteria: * all patients with glaucoma (primary open-angle glaucoma, angle recession glaucoma, exfoliation syndrome glaucoma, pigmentary glaucoma and chronic angle closure glaucoma) in whom a pressure-lowering intervention was conducted exclusion criteria: * inability to obtain reliable field or optical coherence tomography pre-intervention * visual acuity less than 20/40, * age \ 90 years, * other cause for visual field loss not glaucoma, that is, visual field loss due to cataract optic neuropathies, retinal disease * spherical equivalent refractive error \> +5.00 diopters and \> 3.00 diopters cylinder * concomitant cataract and glaucoma surgery

Keywords: visual evoked potentials optical coherence tomography visual fields
gardasil™ post marketing surveillance in the philippines (v501-077)

Conditions: Papillomavirus Infections

Summary: this study will collect safety information on the use of gardasil™ in the philippines.


Eligibility criteria:
inclusion criteria: * received gardasil™
effects of aerobic exercise within a behavioral treatment program for chronic headaches

Conditions: Chronic Headaches

Summary: this proposed study seeks to examine whether adding an aerobic exercise prescription to a behavioral treatment program for chronic headaches will improve headache frequency and intensity, headache-related disability, and mood. it is hypothesized that participants who receive the exercise prescription at the start of treatment will show greater gains than those who receive the prescription halfway through treatment. it is also predicted that participants who begin the exercise component halfway through treatment will demonstrate greater improvement in the second half of treatment compared to the first half.

aerobic exercise has long been discussed as a potential treatment for chronic headaches, though research in this area has been somewhat limited. it is warranted to consider the effectiveness of aerobic exercise as part of a larger headache management intervention. early research in this area suggests that including an exercise component in conjunction with other effective forms of headache management, such as progressive muscle relaxation, biofeedback, and stress management, is associated with improvement in number of days with a headache, headache pain intensity and mood. none of these studies have specifically analyzed the effectiveness of the aerobic exercise component, though lemestra et al. (2002) noted that participants who continued with their exercise regimen had better overall outcomes three months after the intervention ended. given the high rates of obesity and the fact that many people do not meet the minimum daily requirement for exercise, it is worthwhile to investigate the additive effect of exercise to behavioral headache interventions.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic headache (according to international headache association (iha) guidelines) by research personnel * interested in receiving behavioral treatment for chronic headaches * engaged in less than 60 minutes/week of physical activity in the past 3 months * physically capable of engaging in a regular exercise routine * interested in in taking part in a regular exercise routine * regular internet access (at least once a week) exclusion criteria: * males * unable to access internet at least once a week * currently engaging in regular exercise * not interested in participating in regular exercise * not capable of safely exercising * pregnant, nursing, or planning on becoming pregnant during the course of the study * does not meet iha diagnostic criteria for chronic headache * not interested in behavioral headache treatment * diagnosis of medication overuse headache, or headaches related to a physical or neurological disorder * cognitive or other forms of impairment that would decrease ability to fully engage in treatment

Keywords: headaches behavioral treatment physical activity
single dose pharmacokinetic (pk) study of paroxetine cr(12.5-37.5mg) in healthy chinese subjects

Conditions: Depressive Disorder

Summary: the study was designed to describe the relationship between dose and pharmacokinetic parameters of paroxetine over the range of proposed dosage strengths of the paroxetine cr tablet (12.5 to 37.5 mg) as well as safety profile


Eligibility criteria:
inclusion criteria: * 19-45 years healthy chinese * body weight \> 50 kg * bmi between 19-25 * serological negative for hiv, syphilis and hepatitis b and c * no abnormalities in ecg * female with negative pregnancy and male has no plan to have a child during and 3 months after the study. exclusion criteria: * history of chronic physical/mental disease, current disease and concomitant medication

Keywords: brl029060/paroxetine cr pharmacokinetics safety
the natural course of unruptured intracranial aneurysms in a chinese cohort

Conditions: Aneurysm, Intracranial; Natural History

Summary: this is a registry study of the natural course of unruptured intracranial aneurysms (uia). in addition, the investigators will analyze the risk factors for the rupture of the uia and their joint effect. the investigators aim to use research data to create a china national database of uia.

this is a registry study of the natural course of unruptured intracranial aneurysms (uia). in addition, the investigators will analyze the risk factors for the rupture of the uia and their joint effect. the investigators aim to use research data to create a china national database of uia. this study is supported by a research grant from the ministry of science and technology of the people's republic of china. the investigators will collaborate with the other 19 medical centers which locate in the different districts of china. during the study period, all the patients included in this study will observe and treat in the collaborating medical centers. included patients will be followed-up for at least 1year. research data will represent the real natural course of uia in china. for this study, the investigators consulted and hired professional experts about data collection, data and methodology. an intact systematic project steering committee, including data monitoring committee, data management committee, project academic committee, executive group, project manager, project statistician, and technical support center has been built up. scientific regulations have also been made.

Eligibility criteria:
inclusion criteria: 1. diagnosis of untreated unruptured intracranial aneurysm (by cta, mra or dsa) 2. patient with premorbid mrs of 3 or less. 3. patient older than 18 years 4. patient consenting to participate to the study exclusion criteria: 1. subarachnoid hemorrhage with unknown causes 2. patient with other cerebral arteriovenous malformations or cerebral arteriovenous fistulas 3. patient with malignant tumor 4. target aneurysm is fusiform, traumatic, mycotic, or dissecting related. 5. inability to obtain informed consent. 6. patients with a life expectancy less than 1 year 7. participating in the other clinical studies of intracranial aneurysm 8. refusal of follow-up

Keywords: aneurysm, intracranial registries multicenter studies people's republic of china
impact of esmya on fertility to infertile women with fibroids managed with assisted reproduction techniques

Conditions: Infertility, Female; Fibroid Uterus

Summary: fibroid is a frequent pathology of infertile women. its deleterious effect on the infertility would be due to the mechanical way. the interest of the resection of intramural fibroids is discussed. it is necessary to measure the indication of a myomectomy, whatever the surgical procedure. on the one hand, it may cause important potential complications, and on the other hand, the surgery does not improve the parameters of the fertility. thus, it is a major stake to avoid the surgical operation. a decrease of the size of these fibroids by medical treatment is then a good option. when the surgical treatment is necessary, a medical pre-surgical treatment is often proposed in order to decrease the symptomatology and to reduce the size of the fibroid to facilitate the surgery. acetate ulipristal (upa) has been marketed in this indication. following the pearl i-ii studies, the first indication in france was a pre-surgical treatment for 3 months at a dose of 5 mg per day. the pearl iii and iv studies evaluated the esmya® administration as a long-term intermittent repeated treatment, giving to it a prominent position for the long-term management of symptomatic fibroids. furthermore, cases of pregnancy before surgery are frequently described in women with fibroids treated by upa for a pre-ivf surgery. 5 to 10 % of women who are managed for infertility have fibroids and only 2% to 3% have this unique cause of infertility. then, some of patients followed in art centers have been treated by upa to reduce the fibroids size and/or to decrease the associate symptoms. the aim of this study is to evaluate in the different french art centers, the impact on fertilization of upa administration for infertile women with fibroids and to describe the modalities of its prescriptions and to collect information regarding safety tolerance profile of esmya® in this patient population.

a retrospective, national, multicenter study

Eligibility criteria:
inclusion criteria: 1. age between 18 to 43 years 'old at the time of the beginning of ulipristal acetate intake 2. women with fibroid at the time of ulipristal acetate prescription 3. women with desire to have children and managed for infertility in an art center (whatever the type of infertility treatment) 4. women having received a treatment by ulipristal acetate 5. data collected between 2013/12/01 and 2018/06/30 ; data collected between ulipristal acetate prescription until the term of pregnancy or embryo transfer failure (up to 4) or death/lost to follow up or art treatment discontinuation exclusion criteria: none